论文部分内容阅读
目的:探讨帕利哌酮缓释片治疗儿童期首发精神分裂症患者临床疗效及安全性。方法:对37例儿童期首发精神分裂症患者应用帕利哌酮缓释片治疗,观察6个月。采用阳性与阴性症状量表(PANSS)、个人和社会功能量表(PSP)评定临床疗效,并通过治疗满意度调查问卷(MSQ)调查治疗满意度;采用副反应量表(TESS)评定不良反应,并进行实验室监测。结果:观察结束时总有效率为86.5%;PANSS总分、阳性症状分量表、一般精神病理分量表评分于治疗4 d起较治疗前有所下降(P<0.05),于治疗1周末、2周末、3月末、6月末,均较治疗前有显著下降(P<0.01);阴性症状分量表评分于治疗1周时有所下降(P<0.05),于治疗2周末、3月末、6月末,均较治疗前有显著下降(P<0.01)。不良反应轻微,多可自行缓解。社会功能明显改善,治疗满意度为81.1%。结论:帕利哌酮缓释片治疗儿童期首发精神分裂症患者起效快,疗效确切,不良反应轻微,安全性高,依从性好。
Objective: To investigate the clinical efficacy and safety of paliperidone sustained-release tablets in the treatment of first-episode schizophrenia in children. Methods: 37 children with first-episode schizophrenia were treated with Paliperidone extended-release tablets for 6 months. The clinical efficacy was assessed by Positive and Negative Symptom Scale (PANSS), Personal and Social Function Scale (PSP), and the satisfaction of treatment was investigated by the Treatment Satisfaction Questionnaire (MSQ). Adverse reactions were assessed by TESS , And conduct laboratory monitoring. Results: At the end of observation, the total effective rate was 86.5%; PANSS total score, positive symptom subscale and general psychopathological subscale score decreased from 4 d after treatment (P <0.05) (P <0.01). The score of Negative Symptom Scale decreased at 1 week of treatment (P <0.05). At the end of 2 weeks, 3 months and 6 months , Both significantly lower than before treatment (P <0.01). Minor adverse reactions, and more self-remission. Social function improved significantly, treatment satisfaction was 81.1%. Conclusion: Paliperidone sustained-release tablets in children with first-episode schizophrenia have rapid onset, definite curative effect, mild side effects, high safety and good compliance.